Hyperlipidemia Hyperlipoproteinemia Hyperlipoproteinemia (cholesterol, Triglyceride, LDL-C, VLDL)...
-
Upload
garry-gray -
Category
Documents
-
view
226 -
download
2
Transcript of Hyperlipidemia Hyperlipoproteinemia Hyperlipoproteinemia (cholesterol, Triglyceride, LDL-C, VLDL)...
HyperlipidemiaHyperlipidemia
Hyperlipoproteinemia Hyperlipoproteinemia
(cholesterol, Triglyceride, LDL-C , VLDL)(cholesterol, Triglyceride, LDL-C , VLDL)
Lead to atherosclerosis and Coronary Lead to atherosclerosis and Coronary artery disease (CAD)artery disease (CAD)
Hyperlipidemia
Endothelial injuryThrombosis
Atherosclerosis
Smooth muscle cell proliferation
Macrophage inflammatory/immunologic mechanism
AtherosclerosisAtherosclerosis
Atherosclerosis is a disease which Atherosclerosis is a disease which characterized by intimal thickening and characterized by intimal thickening and lipid deposition.lipid deposition.
Definition
AtherosclerosisAtherosclerosis
Hypolipidemic drugsHypolipidemic drugs Bile Acid Sequestering resinsBile Acid Sequestering resins
HMG CoA Reductase InhibitorsHMG CoA Reductase Inhibitors
Fibric Acid DerivativesFibric Acid Derivatives
Nicotinic Acid (Niacin)Nicotinic Acid (Niacin) ProbucolProbucol
CE= cholesteryl ester
Colestyramine, colestipol
Mechanism of action
Binds to bile acid in intestine and prevents its transformation into cholesterol
C l i n i c a l u s e s:
** hypercholesterolemia when a statin is contraindicated
** uses unrelated to atherosclerosis, including:pruritus in patients with partial biliary obstruction
(bile acids that deposit into the skin is responsible for the pruritus)
A d v e r s e e f f e c t s:
GIT symptoms - nauzea, abdominal bloating,نفخ constipation or diarrhea, because resins not absorbed.resins are unappetizing. This can be minimized by suspending them in fruit juice interfere with the absorption of fat-soluble vitamins and drugs (chlorothiazide, digoxin, warfarin)
These drugs should be given at last 1 hour before or 4-6 hours after resin
Effect on LipidsEffect on Lipids
LDL
20-30%
HDL
2-8%
TG
10% (Esp.TG>250mg/dl )
2. HMG CoA Reductase 2. HMG CoA Reductase Inhibitors (Statin)Inhibitors (Statin)
lovastatinatorvastatinpravastatinsimvastatinFluvastatin
Rosuvastatin
Mechanism of StatinMechanism of Statin
Specific competitive inhibitor to HMG CoA Specific competitive inhibitor to HMG CoA Reductase Enzyme which is the rate limiting Reductase Enzyme which is the rate limiting step in cholesterol biosynthesisstep in cholesterol biosynthesis
The synergism effect of statin The synergism effect of statin and resinand resin
Effect on LipidsEffect on Lipids
LDL
25-55%
HDL
5-10%
TG• 10-20% (triglycerides < 250 mg/dl)
• 35-45% (triglycerides > 250 mg/dl)
A d v e r s e e f f e c t s A d v e r s e e f f e c t s
- mild gastrointestinal disturbancesmild gastrointestinal disturbances
- increased plasma activities in liver increased plasma activities in liver enzymesenzymes
- severe myositis (rhabdomyolysis) severe myositis (rhabdomyolysis)
andand angio-oedema (rare) angio-oedema (rare)
Clinical Use
• Hyperlipidemia
•In atherosclerosis
3. Fibric acid derivatives 3. Fibric acid derivatives (fibrates)(fibrates)
Clofibrategemfibrozil fenofibratebezafibrate ciprofibrate
Mechanism of actionMechanism of action
- - - increase the activity of lipoprotein lipase, - increase the activity of lipoprotein lipase, hence increasing hydrolysis of triglyceride in hence increasing hydrolysis of triglyceride in
chylomicrons and VLDL particles. chylomicrons and VLDL particles. - reduce hepatic VLDL production reduce hepatic VLDL production andand increase increase
hepatic LDLhepatic LDL uptake.uptake.- Produce a modest decrease in LDL (~ 10%) and Produce a modest decrease in LDL (~ 10%) and
increase in HDL (~ 10%).increase in HDL (~ 10%).- But, a marked decrease in TGs (~ 30%).But, a marked decrease in TGs (~ 30%).
Effect on LipidsEffect on Lipids
TGTG
25-40%25-40% HDLHDL
5-15%5-15% LDLLDL
15-20% 15-20%
ToxicityToxicity
GIGI nausea., vomiting, gall stonenausea., vomiting, gall stone
Skeletal MuscleSkeletal Muscle Myopathy, weakness (Myopathy, weakness (Esp. with Esp. with StatinsStatins))
LiverLiver Increase aminotransferaseIncrease aminotransferase
Hematologic changeHematologic change Anemia, leukopeniaAnemia, leukopenia
Uses: Uses:
1st-line defense for:1st-line defense for:
*mixed dyslipidemia(i.e. raised serum TG and CHO)
* patients with low HDL and high risk of atheromatous disease (often type 2 diabetic patients)
* patients with severe treatment- resistant dyslipidemia (combination with other lipid-lowering drugs).* Indicated in patients with VERY HIGH [TG]s who are at risk for pancreatitis
nicotinic acid (vitamin B3) Water soluble vitamin Nicotinic acidNicotinic acid acts by acts by decreasingdecreasing esterification of esterification of hepatichepatic
TGTG, and increasing the activity of , and increasing the activity of lipoproteinlipoprotein lipase .lipase . It decreasesIt decreases hepatic TG production hepatic TG production andand VLDL Secretion VLDL Secretion
(by ~ 30-50%) (by ~ 30-50%) modest reduction in LDL modest reduction in LDL andand increase in increase in HDLHDL.. Nicotinic Nicotinic
acid was the 1st lipid-lowering drug to acid was the 1st lipid-lowering drug to decrease decrease mortality mortality in in patients with CAD.patients with CAD.
A d v e r s e e f f e c t s:A d v e r s e e f f e c t s: flushing, palpitations , GIT disturbances.flushing, palpitations , GIT disturbances.
Currently, nicotinic acid is rarely used.Currently, nicotinic acid is rarely used.
OtherOther LIPID-LOWERING DRUGS
Fish oil (rich in highly unsaturated fatty acids)
the omega-3 marine TG - reduce plasma TG but increase CHO (CHO is more strongly associated wih coronary artery disease)-the effects on cardiac morbidity or mortality is unproven( although there is epidemiological evidence that eating fish regularly does reduce ischemic heart disease)
Ezetimibe:Ezetimibe:
Inhibitors of Intestinal CHO Absorption:
Reduces CHO absorption and decreases LDL with little change in HDL
May be synergistic with statins: so good for combination therapy.
A potent lipophilic antioxidantA potent lipophilic antioxidant
Probucol
A t h e r o g e n e s i s involves several stages:- endothelial dysfunction with altered PGI2 and NO synthesis-endothelial cells monocyte attachment- bind LDL- oxidatively modified LDL is taken up by macrophages- having taken up oxidised LDL, these macrophages (now foam cells) migrate subendothelially- atheromatous plaque formation- rupture of the plaque
HDL Prevent Foam Cell FormationHDL Prevent Foam Cell Formation
LDLLDL
LDLLDL
EndotheliumEndothelium
Vessel LumenVessel LumenMonocyteMonocyte
Modified LDLModified LDL
MacrophageMacrophage
MCP-1MCP-1AdhesionAdhesionMoleculesMolecules
CytokinesCytokines
IntimaIntimaHDL Promote Cholesterol EffluxHDL Promote Cholesterol Efflux
Foam Foam CellCell